<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589691</url>
  </required_header>
  <id_info>
    <org_study_id>FDE_2014_25</org_study_id>
    <nct_id>NCT02589691</nct_id>
  </id_info>
  <brief_title>Neuromuscular-Blocking Agents and Hypoxemia During Intubation in Infants (ROC-HYPOX)</brief_title>
  <acronym>ROC-HYPOX</acronym>
  <official_title>Addition of Neuromuscular-Blocking Agents During Sevoflurane Induction in Infants : Potential Interest in Reducing Hypoxemia Episodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      The prevention of the occurrence of respiratory events is a constant concern in pediatric&#xD;
      anesthesia, as these represent the main cause of the anesthesic mortality. These events occur&#xD;
      partly during induction of anesthesia and are all the more frequent as the child is young.&#xD;
&#xD;
      The French recommendations do not propose the use of neuromuscular-blocking agents in&#xD;
      pediatric anesthesia. This recommendation is controversial In a recently published study, it&#xD;
      has been shown that the use of neuromuscular blocking agents during induction in children&#xD;
      under 2 years improves intubating conditions and reduces the incidence of hemodynamic and&#xD;
      respiratory events. This monocentric study, centered on intubating conditions, does not allow&#xD;
      to conclude on the influence of muscle relaxants on reduction of the respiratory morbidity.&#xD;
&#xD;
      The objective of study is to demonstrate that, in children under 2 years, changing the&#xD;
      anesthesia protocol can reduce the incidence and severity of episodes of hypoxemia associated&#xD;
      with respiratory events occurring during induction&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2015</start_date>
  <completion_date type="Anticipated">December 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, expressed as a percentage, of at least on episode of hypoxemia, defined as an arterial oxygen saturation &lt;90%, obtained by continuous measurement of pulse oximetry.</measure>
    <time_frame>Up to 15 minutes after anesthesia induction</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of hypoxemia expressed in seconds and defined as an arterial oxygen saturation &lt;90%</measure>
    <time_frame>Up to 15 minutes after anesthesia induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration, expressed in seconds, with a decreased in arterial oxygen saturation of 5% as compared to the arterial oxygen saturation at baseline</measure>
    <time_frame>Up to 15 minutes after anesthesia induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest recorded value of arterial oxygen saturation.</measure>
    <time_frame>Up to 15 minutes after anesthesia induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, expressed as a percentage, of at least one episode of bronchospasm</measure>
    <time_frame>Up to 15 minutes after anesthesia induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, expressed as a percentage, of at least one episode of laryngospasm</measure>
    <time_frame>Up to 15 minutes after anesthesia induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration, expressed in seconds, of apnea</measure>
    <time_frame>Up to 15 minutes after anesthesia induction</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">412</enrollment>
  <condition>Hypoxemia</condition>
  <arm_group>
    <arm_group_label>Rocuronium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-venous injection during induction anesthesia of 0.3 mg/kg (1 mL/kg) of rocuronium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intra-venous injection during induction anesthesia of 1 mL/kg of sodium chloride 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <arm_group_label>Rocuronium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium chloride 0.9%</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &lt;2 years&#xD;
&#xD;
          -  indication of general anesthesia with tracheal intubation&#xD;
&#xD;
          -  inhalational induction scheduled&#xD;
&#xD;
          -  written informed consent of both parents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contra-indication to inhalational induction (full stomach)&#xD;
&#xD;
          -  contra-indication to the use of rocuronium&#xD;
&#xD;
          -  American Society of Anesthesiologists score (ASA) III or IV&#xD;
&#xD;
          -  intracranial surgery&#xD;
&#xD;
          -  parental refusal&#xD;
&#xD;
          -  absence of affiliation to social security&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Creteil (CHIC)</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Veyckemans, Dr</last_name>
      <phone>03 20 4463 23</phone>
      <email>francis.veyckemans@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Orliaguet</last_name>
      <email>gilles.orliaguet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation ophtalmique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Salomon, MD, PhD</last_name>
      <phone>+33 1 48 03 64 31</phone>
      <email>lsalomon@fo-rothschild.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Debre</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Souhayl DAHMANI, Pr</last_name>
      <phone>0140032020</phone>
      <email>souhayl.dahmani@rdb.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 27, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

